
Both the ZUMA-7 trial for axicabtagene ciloleucel—approved for second-line treatment earlier this year—and the TRANSFORM trial for lisocabtagene maraleucel showed significant improvement over standard of care for large B cell lymphoma (LBCL), while the BELINDA trial for tisagenlecleucel did not.



























